DOI: http://dx.doi.org/10.18203/2349-2902.isj20174899

Association between serum linezolid concentration and haematological toxic effects: a longitudinal study

Prashant R. Hombal, Anupama M. Gudadappanavar, S. B. Javali

Abstract


Background: Linezolid is a commonly used antibiotic and reported various drug related adverse effects mainly haematological toxicity like thrombocytopenia, leukopenia and anaemia. But a significant association between linezolid plasma concentration and drug related adverse effects are not documented yet. This longitudinal observational study aims to study the incidence of drug related haematological toxicities and its association with serum Linezolid concentration and also evaluate the clinical outcome.

Methods: After obtaining informed consent, each patient (18-50years) was given linezolid (600mg/12hourly), and evaluated for haematological (haemoglobin, platelets, WBCs), renal (as serum creatinine), and hepatic (as serum transaminases status), together with an assessment of drug C min values. These evaluations were repeated once a week or in concomitance with the development of an adverse event up to the end of linezolid therapy. The parametric dependent ‘t’ test was applied (p<0.05) and normality of data were performed by Kolmogorov Smirnov test, follows normal distribution.

Results: There was significant reduction in platelet count and haemoglobin value seen from baseline till end of treatment (p<0.001) and there was 13% reduction in WBC count in all patients on day 14 when compared to baseline (p<0.001) indicating haematological toxicity according to WHO toxicity grading scale. All the patients (n=8; 26.6%) who developed drug related haematological toxicity also showed comparable increase in plasma linezolid concentration (C min) >10mg/L at the end of 14days.

Conclusions: The capability to monitor plasma linezolid concentration (C min; trough value) once a week may lead to a significant improvement in clinical use of the drug both in terms of efficacy and tolerability as the study observed that there is association between linezolid concentration and risk of developing drug related haematological toxicity.


Keywords


Adverse effects, Gram positive infection, Haematological toxicity, Linezolid, Plasma trough concentration, Safety outcome

Full Text:

PDF

References


Brunton LL, Laso JS, Parker KL. Goodman Gilman A. The Pharmacological Basis of Therapeutics. 12th ed. New York: McGraw Hill. 2011.

Tripati KD. Essential of Medical Pharmacology, 7th ed. New Delhi, India: Jaypee Brothers Medical Publishers, 2014:752-764.

Di Paolo A, Malacarne P, Guidotti E, Danesi R, Del Tacca M. Pharmacological issues of linezolid an updated critical review. Clin Pharmacokinet. 2010;49(7):439-47.

Watkins RR, Lemonovich TL, File TM. An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy. Core Evidence. 2012;7:131-43.

Stevens DL, Dotter B, Madaras-Kelly K. A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti Infect Ther. 2004;2(1):51-9.

Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med. 2003;138:135-42.

Beekmanna SE, Gilbertb DN, Polgreena PM. Toxicity of extended courses of linezolid: results of an infectious diseases society of america emerging infections network survey. Diagnostic Microbiology and Infectious Disease. 2008;62:407-10.

Pea F, Viale P, Cojutti P, Del Pin B, Zamparini E, Furlanut M. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother. 2012;67:2034-42.

Zoller M, Maier B, Hornuss C, Neugebauer C, Döbbeler G, Nagel D, et al. Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study. Critical Care. 2014;18:148.

Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Available at http://www.fda.gov/downloads/BiologicsBloodVaccines/ucm091977. Accessed 22 Feb 2017.

Drugs: From Discovery to Approval. Toxicity grading[internet] Second Edition; 2008 April 30. Available at http://onlinelibrary.wiley.com/doi/10.1002/9780470403587.app8/pdf. Accessed on 22 Feb 2017.

Conte JE, Golden JA, Kipps J, Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrobial Agents Chemotherapy. 2002;46(5):1475-80.

Boak LM, Li J, Nation RL, Rayner CR. High‐performance liquid chromatographic method for simple and rapid determination of linezolid in human plasma. Biomedical Chromatography. 2006;20(8):782-6.

De Vriese AS, Van Coster R, Smet J, Seneca S, Lovering A, Van Haute LL, et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clinical infectious diseases. 2006;42(8):1111-7.

Watkins RR, Lemonovich TL, File TM. An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy. Core Evidence. 2012;7:131-43.

Bi LQ, Zhou J, Huang M, Zhou SM. Efficacy of linezolid on gram-positive bacterial infection in elderly patients and the risk factors associated with thrombocytopenia. Pakistan J Med Sci. 2013;29(3):837.

Bishop E, Melvani S, Howden BP, Charles PG, Grayson ML. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrobial Agents Chemotherapy. 2006;4:1599-602.

Moraza L, Leache L, Aquerreta I, Ortega A. Linezolid-induced haematological toxicity. Farm Hosp. 2015;39(6):320-32.

Gorchynski JA, Rose JK. Complications of MRSA treatment: linezolid-induced myelosuppression presenting with pancytopenia. Western J Emergency Med. 2008;9(3):177.

McKee EE, Ferguson M, Bentley AT, Marks TA. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrobial Agents Chemotherapy. 2006;50(6):2042-9.

Pea F, Furlanut M, Cojutti P, Cristini F, Zamparini E, Franceschi L, et al. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrobial Agents Chemotherapy. 2010;54(11):4605-10.

Wu VC, Wang YT, Wang CY, Tsai IJ, Wu KD, Hwang JJ, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis. 2006;42(1):66-72.

Zhang YM, Yu W, Zhou N, Li JZ, Xu LC, Xie ZY, et al. High frequency of thrombocytopenia in patients with acute-on-chronic liver failure treated with linezolid. Hepatobiliary Pancreatic Dis Int. 2015;14(3):287-92.